Mecasermin clinical trials
Also written Increlex and insulin-like growth factor I.
How each study uses mecasermin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mecasermin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Aug 2005 · INCRELEX · BLA 021839 (FDA, Drugs@FDA)
- European Union
- 2 Aug 2007 · Increlex · EMEA/H/C/000704 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2011 (7)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1995 | 2 |
| 1997 | 1 |
| 1998 | 1 |
| 2000 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 7 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 27
Ipsen (5) · Massachusetts General Hospital (4) · Children's Hospital Medical Center, Cincinnati (2) · Icahn School of Medicine at Mount Sinai (2) · Boston Children's Hospital (2) · Children's Hospital of Philadelphia (2) · Bispebjerg Hospital (2) · The University of Texas Medical Branch, Galveston (1)
Often tested with
Tested in the same studies.
Rinfabate (2) · Insulin (1) · Oxandrolone (1) · Propranolol (1) · Growth Hormone (1) · Insulin-Like Growth Factor Binding Protein 3 (1) · Itraconazole (1) · Estradiol (1)
Studies
Open first, then newest update. How each study uses mecasermin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 34
- Gene Expression Changes In Young and Geriatric SkinRecruitingEarly Phase 1Wright State UniversityNCT03932162Written as Insulin-Like Growth Factor 1How we know
- Increlex Treatment of Children With Chronic Liver Disease and Short StatureWithdrawnNot applicableUniversity of California, Los AngelesNCT01314508Written as IncrelexHow we know
- Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk FactorsTerminatedPhase 1/2Columbia UniversityNCT00684957Written as Recombinant Human IGF-1How we know
- IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 DeficiencyCompletedPhase 1/2Children's Hospital Medical Center, CincinnatiNCT02636270Written as IncrelexHow we know
- A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum DisorderTerminatedPhase 2Icahn School of Medicine at Mount SinaiNCT01970345Written as IGF-1How we know
- Long-Term Treatment With rhIGF-1 in GHISCompletedPhase 2/3IpsenNCT00571727Written as mecaserminHow we know
- Assessment of Mechanisms of Improved Wound HealingCompletedPhase 2/3The University of Texas Medical Branch, GalvestonNCT00673309Written as IGF-1/IGFBP-3How we know
- rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 DeficiencyTerminatedPhase 2IpsenNCT00572156Written as Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])How we know
- Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)CompletedPhase 2ShireNCT02386839Written as rhIGF-1/rhIGFBP-3How we know
- Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)CompletedPhase 2Icahn School of Medicine at Mount SinaiNCT01525901Written as Insulin-Like Growth Factor-1 (IGF-1)How we know
- Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia NervosaCompletedPhase 2Massachusetts General HospitalNCT00720122Written as Recombinant human insulin like growth factor-1 (rhIGF-1)How we know
- Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in AdolescentsCompletedPhase 1/2Massachusetts General HospitalNCT00516386Written as RhIGF-1How we know
- Effects of Anorexia Nervosa on Peak Bone MassCompletedPhase 3Massachusetts General HospitalNCT01301183Written as RhIGF-1 with transdermal 17-beta estradiolHow we know
- Safety and Efficacy Study of IGF-1 in Duchenne Muscular DystrophyCompletedPhase 1/2Children's Hospital Medical Center, CincinnatiNCT01207908Written as IGF-1How we know
- Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 DeficiencyTerminatedPhase 3IpsenNCT00330668Written as rh IGF-1 (mecasermin)How we know
- Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-IStatus unknownEarly Phase 1Bispebjerg HospitalNCT01834989Written as Insulin-like growth factor IHow we know
- Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 DeficiencyCompletedPhase 2/3IpsenNCT00125190Written as rhIGF-1 (mecasermin) for a period of 86 weeksHow we know
- IGF-1 and Bone Loss in Women With Anorexia NervosaCompletedNot applicableMassachusetts General HospitalNCT01406444Written as rhIGF-1How we know
- Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) DeficiencyCompletedPhase 3IpsenNCT00125164Written as rhIGF-1 (mecasermin, Tercica, Inc.)How we know
- Treatment of Rett Syndrome With Recombinant Human IGF-1CompletedPhase 2Boston Children's HospitalNCT01777542Written as Recombinant Human Insulin Growth Factor 1 (rhIGF-1)How we know
Codes
What other systems call mecasermin · ClinicalTrials.gg INT000380
- MeSH (NLM) C000604197mecaserminConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7GR9I2683OMECASERMINConfirmed FDA, NLM, Wikidata
- RxNorm 274403Confirmed FDA, Wikidata
- Wikidata Q6804390mecaserminConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2262MecaserminConfirmed FDA, Wikidata
- DrugBank DB01277One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604197 | mecasermin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7GR9I2683O | MECASERMIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 274403 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6804390 | mecasermin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2262 | Mecasermin | Confirmed FDA, Wikidata |
| DrugBank | DB01277 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.